CABS
CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY
北美华人生物医药协会

CABS BIOPACIFIC CONFERENCE 2025

2025 BIOPACIFIC CONFERENCE

Frontiers in Healthcare: Forging Global Impact Through Science, Innovation, and Partnership

Sept. 13, 2025

26TH ANNUAL BIOPACIFIC CONFERENCE
SOUTH SAN FRANCISCO CONFERENCE CENTER

CABS
CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY
北美华人生物医药协会

TABLE OF CONTENTS

**English is the official working language of the conference.*

BIOPACIFIC 2025 CONFERENCE

CABS Contact Information

Mailing Address
268 Bush Street, #1888
San Francisco, CA 94104, USA

Website
http://www.cabsweb.org

Emails

For General information
Info@CABSweb.org

For Membership
Membership@CABSweb.org

For Fundraising
Fundraising@CABSweb.org

Program Book Production

Chief Editor
Liang He

Editors
Sihong Zhou
Shicheng Guo
Zhiqing Wang
Ya'nan Wang
Vivian Liu

Graphic Design
Xiaojun Li

2025 BioPacific Conference Organizing Committee

cabsweb.org

SPONSORS - 2025 CABS BIOPACIFIC CONFERENCE

Long-Term Partner

KENSON VENTURES

Diamond Sponsors

全和诚 COSYCHEM

HitChem

Platinum Sponsors

MORRISON FOERSTER

15 Year Long-Term Sponsor

abbvie

APELOA

Haier Biomedical
Intelligent Protection of Life Science

Gold Sponsors

gator

康龙化成 PHARMARON

Silver Sponsors

OBiO CELL & GENE THERAPY CRO & CDMO

KACTUS

WISKIND CLEANROOM SYSTEM

Novogene

Badge/Lanyard Sponsor

PRECEDO

ABclonal Technology

SynChem FORMOSA LABORATORIES, INC.

BladeBio

江苏无锡（惠山）生命科技产业园
L-PARK

KYINNO Biotechnology

HANHAI BIOLABS

瀚海 · 无锡

BioProMind
www.biochains.com

ChemShuttle
Synthesizing Life

3H Science
CRO Lab, HPLC/LCMSMS/ELISA

Exhibitors

Media Partners

Our Vision/Mission

- *To SERVE as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries*
- *To SERVE life science professionals to promote professional interactions locally and across the Pacific*
- *To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim Countries*
- *To PROMOTE public awareness of progress and development in the life sciences industry*
- *To COLLABORATE with other organizations in areas of mutual interest*

About CABS

Chinese American Bio/Pharmaceutical Society (CABS)

The Chinese American Bio/Pharmaceutical Society (CABS) is a non-profit organization for professionals in the bio/pharmaceutical industry. CABS is headquartered in the San Francisco Bay Area, California. This is the home of Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand bio/pharmaceutical/biotech companies in this area, including several large bio/pharmaceutical companies such as Amgen, Genentech, and Gilead. CABS is a highly influential association with more than 3,500 members and 20,000 subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences. A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists, or investors in the life sciences sector. CABS is one of North America's most active largest bio/pharmaceutical associations. We organize many activities to promote international collaborations in life sciences. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of bio/pharmaceutical professionals and business leaders.

CABS Member Demographics

• Founded in 1998, a volunteer-based, non-profit organization for professionals in life sciences
• Headquartered in the San Francisco Bay Area
• 3,500+ members and 20,000+ subscribers in 30+ countries

By Position



By Degree



By Function



By Seniority



By Industry



Remarks from the President of CABS Chinese American Bio/Pharmaceutical Society (CABS)

Kay Tong, MA
President-Elect of CABS

Welcome CABS Members, Friends, and Supporters,

As this year's President, it is with great pride and enthusiasm that I welcome you to another vibrant year with the Chinese American Bio/Pharmaceutical Society (CABS). As we reflect on 2025, we are deeply grateful for your continued engagement and for sharing in our mission: to connect life science professionals, promote cross-Pacific collaboration, and advance public awareness and innovation in biotechnology and healthcare.

This year, CABS has continued to fulfill its mission through a series of impactful programs and milestones.

1.Serving Life Science Professionals

The year began with turbulent waters with another winter in pharmaceutical investment and a series of layoffs. CABS took the opportunity to serve its members in the Life Sciences to promote professional interactions locally and across the Pacific through our workshops in entrepreneurship, career development, interview skills and mentorship programs there by creating new opportunities for our members and life science professions. The workshops enabled our members and life science professionals to connect professionally, establish new career paths, and foster collaboration opportunities locally and throughout the Pacific Rim.

2. Fostering Life Science Business Opportunities Globally

At the beginning of the year, CABS had several hallmark events during the week of JP Morgan Healthcare Conference focusing on promoting cross border innovation and business exchange. Our committees including our International Collaboration, Alliance Management, Science & Technology, and Business & Career Development focused on promoting cross-border partnerships in sponsorships, job opportunities, business development and partnerships through our workshops and programs this year. All committees highlighted the opportunities globally in biopharmaceuticals to support our members and life science professionals in new endeavors. CABS continues to lay down the groundwork to support such successful partnerships globally.

3. Promoting Life Science Progress and Development

CABS continues to educate members and life science professionals globally through webinars and seminars from our different committees. In-person seminars are consistently full packed in conference rooms and our international global webinar had an attendance of over 300 people educating professionals from patent requirements, cross-boarder funding opportunities, exit strategies, clinical science, regulatory landscapes, business development, and career development. Success stories including lessons learned from panel discussions provided our members and life science professionals knowledge and real-world examples to navigate strategically for the next success in their own professional career.

4. Strengthening Through Collaboration

A time honored tradition of CABS is our Chinese New Year Gala, Dragon Boat Race, and Barbecue hosted by our Social Life Committee. These social events bring our members and life science professionals together to foster collaborations in areas of mutual interest socially and create opportunities to build connections and bridges professionally. Alongside sister organizations and sponsors for CABS we collaborate to bring our members and professionals together to network. The success of such events and opportunities to network is through the promotion of our Public Relations and Operations Committees.

The 100% volunteer- based CABS community thrives because of your commitment, curiosity, and passion. As we look ahead to 2026, we remain steadfast in our vision: to serve as a bridge connecting life science professionals, businesses, and communities across the U.S. and the Pacific Rim.

Thank you for being a part of CABS. Together, we will continue to elevate global biomedical innovation, one connection at a time.

Warm regards,

Kay Tong

Kay Tong, MA
2025 President, Chinese American Bio/Pharmaceutical Society (CABS)

Remarks from the Chair of 2025 BioPacific Conference Organizing Committee, President-Elect of CABS

Sihong Zhou
President-Elect of CABS

Welcome to the 2025 BioPacific Conference,

It is my great honor to serve as the President-Elect of the Chinese American Bio/Pharmaceutical Society (CABS) and Chair of this year's Organizing Committee. I am truly delighted to welcome each of you to the 26th Annual BioPacific Conference.

Over the past two decades, this conference has become a cornerstone event in our community - an essential platform for advancing scientific innovation, fostering professional collaboration, and building lasting partnerships across the bio/pharmaceutical landscape.

The theme of this year's conference, "Frontiers in Healthcare: Forging Global Impact Through Science, Innovation, and Partnership," reflects the profound transformation underway in our field. With the rapid advancement of technologies such as artificial intelligence, the explosion of scientific data, and the increasing significance of global collaboration, we are entering a new era filled with unprecedented opportunities. From drug discovery and diagnostics to clinical development and commercialization, the boundaries of what is possible in healthcare are continuously expanding.

We are proud to recognize Dr. Liqun Luo, Professor at Stanford University, as the recipient of the 2025 K. Fong Award. Dr. Luo is a world-renowned neuroscientist whose groundbreaking research has significantly advanced our understanding of neural circuit development and function. His widely used textbook, Principles of Neurobiology, and his many accolades - including election to the National Academy of Sciences and the American Academy of Arts and Sciences—reflect his deep and enduring impact on the field. At today's conference, Dr. Luo will share his recent work linking thirst to motivated behavior and exploring neural dynamics underlying thirst motivation, and how animals resolve competing needs, such as thirst and hunger, across time. Abnormal regulation of this process could lead to psychiatric disorders.

This year's conference is further distinguished by the presence of two esteemed keynote speakers. Dr. Howard Chang, Chief Scientific Officer and Senior Vice President of Global Research at Amgen, is an internationally recognized physician-scientist and a pioneer in regulatory RNA biology. His keynote, RNA Origin of Sex Biased Immunity, will examine the striking differences between men and women in immune responses - highlighting how a female-specific RNA plays a pivotal role in driving female-biased immunity. This discovery not only sheds light on why women are disproportionately affected by autoimmune diseases but also opens new avenues for technology development, diagnostics, and therapeutic strategies. Joining him is Dr. Margaret Porter Scott, Vice President of Biochemical and Cellular Pharmacology at Genentech. With over two decades of experience in drug discovery, Dr. Scott has played a pivotal role in the development of targeted therapies, including the recent approval of inavolisib for breast cancer. Her keynote will explore Genentech's strategic initiatives to accelerate drug discovery and translational science.

Complementing the keynote addresses, the program also features a series of exceptional presentations from leaders in both academia and industry. Dr. Hans-Peter Gerber of Sutro Biopharma will highlight advances in dual-payload antibody-drug conjugate (ADC) development using Sutro's cell-free expression platform. Dr. Lei Xing of Stanford University will demonstrate how artificial intelligence and foundation models are being applied to multi-omics data to enable precision oncology. Dr. Su Guo of UCSF will present novel strategies for targeting GPCR signaling in Parkinson's disease.

This year, CABS is pleased to host three engaging panel discussions that address critical and timely topics in today's biopharmaceutical ecosystem: the application of artificial intelligence in drug discovery, cross-border healthcare investment, and innovation in biotech startups. These sessions will bring together diverse perspectives from academia, industry, and venture capital, fostering meaningful dialogue and new collaborations.

On behalf of the Organizing Committee, I extend my sincere gratitude to all of our speakers, sponsors, volunteers, and partners for their dedication and contributions. And to you—our attendees—thank you for being part of this vibrant and forward-thinking community.

Sihong Zhou

Sihong Zhou
Chair of 2025 BioPacific Conference Organizing Committee
President-Elect of CABS

2025 CABS Leadership

Board of Directors

- **Kay Tong, MA**, Chief Executive Officer, N2N GXPS4U
- **Yuying "Kate" You, PhD, JD**, Patent Attorney, Morrison Foerster LLP
- **Carrie Wang, MD,** Vice President, ARC Medical Inc
- **Yan Wang, PhD**, Executive Director, Lepu Biopharma
- **Alex J. Zhang, PhD, MBA**, Founder & CEO, OneTwenty Therapeutics
- **Cheni Kwok, PhD, CLP**, Managing Partner, Linear Dreams
- **Alan Hao, PhD, CEO**, AIM Biosciences
- **Zhonghua Pei, PhD**, Senior VP of Drug Discovery at Lyterian Therapeutics
- **Janet Xiao, PhD, JD**, Partner, Morrison & Foerster LLP
- **Wentao Zhang, PhD**, Founder& President, Quintara Discovery; Co-CEO of Frontage Laboratories, Inc.
- **Wei Dong, MD, PhD**, VP and Head of Drug Safety, Denali Therapeutics
- **Jing-Shan "Jennifer" Hu, PhD**, Former Senior Advisor & Founding Partner, Qiming U.S. Healthcare Fund

2025 Executive Council Office of the President

- **President: Kay Tong, MA,** Chief Executive Officer, N2N GXPS4U
- **President-Elect: Sihong Zhou,** Senior Scientist, Sutro Biopharma
- **Past President: Jessica Sun, MD, PhD** Executive Director, Terremoto Biosciences

2025 CABS **Leadership**

Office of Operations (O2)

- **Chair: Liang He, PhD,** Scientist, Frontage
- **Advisors: Vivian Liu, PhD,** Lab Director, Novogene America
  Shicheng Guo, PhD, Senior Director, Arrowhead Pharmaceuticals
- **Members: Katherine Guan,** Scientist II, AbbVie
  Zhuoqing Fang, PhD, Research Engineer, Stanford
  Zuolin Cheng, PhD, Research Associate, Virginia Tech
  Yang Ma, College Student, UCSD

Membership (MEM)

- **Co-Chairs: Vivian Liu, PhD,** Lab Director, Novogene America
  Amy Yang, Scientist, Bayer
- **Advisors: Wenjia Gu, PhD,** Scientist, Sutro Biopharma
  Yuki Yang, Research Associate II - Vaxart Inc
- **Member: Katherine Guan,** Scientist II, AbbVie

Public Relations & Communications Committee (PRC)

- **Co-Chairs: Shicheng Guo, PhD,** Senior Director, Arrowhead Pharmaceuticals
  Zhiqing Wang, PhD, Scientist, Metagenomi
- **Advisor: Liang He, PhD,** Scientist, Frontage
- **Members: Lillian Jiang,** Account Manager, Vazyme
  Lin Song Kretschmer, Post Doc, UCSF
- **Volunteers: Yuan Li, Ying Yang, Yi Zhong, Kaiqing Zhang, Lingfei Wang, Lu Zhou**

Alliance Management Committee (AMC)

- **Co-Chairs: Yanan Wang, PhD,** Senior Scientist, QLSF Biotherapeutics
  Le Cai, PhD, Scientist, A&P Inphatec
- **Advisor: Denna Kwang,** Sales Account Manager, ABclonal Technology
- **Members: Mingdian Tan, PhD,** Research Scientist, Stanford University
  Peng'an Liu, Associate Scientist II, Propeller Bio
  Yujiao Zhang, PhD, Business Development Manager, KACTUS
  Zheng Cai, PhD, Independent Consultant
  Tim Tian, Independent Consultant

Science & Technology Committee (STC)

- **Co-Chairs: Liping Meng, PhD**, Principal Scientist II, Gilead Sciences
  Lifei "Alex" Yang, PhD, Senior Scientist, Vir Biotechnology
- **Advisor: Yan Wang, PhD**, Senior Director, Peptide Chemistry, Stealth Mode Biotech
- **Members: Weibin Zheng, MS,** Business Development, Vazyme Biotech
  Zheng Cai, PhD, Independent Consultant

International Collaboration Committee (ICC)

- **Co-Chairs: Yu Yang, MS,** CEO, Hanhai Silicon Valley Center
  Guanghui Han, PhD, Head of Proteomics, PTM Bio LLC
- **Members: Lingling Peng, PhD,** Scientist, Genentech
  Tim Tian, Independent Consultant

Business & Career Development Committee (BCD)

- **Co-Chairs: Wenjia Gu, PhD,** Scientist, Sutro Biopharma
  Yan Wang, PhD, Senior Director, Peptide Chemistry, 280 Bio
- **Advisor: Guanghui Han, PhD,** Head of Proteomics, PTM Bio LLC
- **Members: Feng Pan, PhD,** President/Co-Founder, LexigenBio
  Weibin Zheng, MS, Business Development, Vazyme Biotech
  Yujiao Zhang, PhD, Senior Business Development Manager, KACTUS
- **E-Club Co-Chairs: Lu Lu, MS,** Senior Director of Business Development, MicuRx Pharmaceuticals
  Jack Zhu, MBA, Associate Director, Sales Analytics, Gilead Sciences
- **E-Club Advisor: Huijun Zhou, PhD,** Adjunct Professor, Stanford University
- **E-Club Members: Jonathan Wong,** Founder, Enigma Search
  Yuki Yang, Research Associate II - Vaxart Inc;
  Yue Wang, PhD, Associate Director of Business Development, Lonza Biologics
  Shiping Wang, Business Development Manager, WuXi AppTec
- **CAN Co-Chairs: Jonathan Wong,** Founder, Enigma Search
  Feng Pan, PhD, President/Co-Founder, LexigenBio
- **CAN Advisor: Xinxin Li,** Volunteer
- **CAN Members: Peng'an Liu,** Assoc. Scientist II, Propeller Bio, Inc.
  Zuolin Cheng, PhD, Postdoc Research Associate, Virginia Tech

Social Life Committee (SLC)

- **Co-Chairs: Li Wang,** Manager, Arcus Biosciences
  Crystal Tan, MS, Nurse at Ophthalmology, San Francisco General Hospital
- **Advisor: Xinxin Li, MS,** VP, MyBioGate;
- **Members: Mingdian Tan, PhD,** Postdoc, Stanford University
  Yuki Yang, Research Associate II - Vaxart Inc;
  Lingling Peng, PhD, Scientist, Genentech

Web Masters:

- **Shicheng Guo, PhD,** Senior Director, Arrowhead Pharmaceuticals
- **Zuolin Cheng, PhD,** Research Associate, Virginia Tech

Accountant

- **Yao Long**

2025 BioPacific Conference
Organizing Committee

Sihong Zhou, President-Elect, CABS; Senior Scientist, Sutro Biopharma

Kay Tong, MA, President, CABS; Chief Executive Officer, N2N GXPS4U

Liang He, PhD, Scientist, Frontage

Shicheng Guo, PhD, Senior Director, Arrowhead Pharmaceuticals

Yan Wang, PhD, Senior Director, Peptide Chemistry, 280 Bio

Zhiqing Wang, PhD, Scientist, Metagenomi

Liping Meng, PhD, Principal Scientist II, Gilead Sciences

Le Cai, PhD, Scientist, A&P Inphatec

Fiona Yu, Director of Finance, Complete Genomics

Ya'nan Wang, PhD, Senior Scientist, QLSF Biotherapeutics

Wenjia Gu, PhD, Scientist, Sutro Biopharma

Vivian Liu, PhD, Lab Director, Novogene America

Lifei "Alex" Yang, PhD, Senior Scientist, Vir Biotechnology

Lu Lu, MS, Senior Director of Business Development, MicuRx Pharmaceuticals

Guanghui Han, PhD, Head of Proteomics, PTM Bio LLC

Amy Yang, Scientist, Bayer

Feng Pan, PhD, President/Co-Founder, LexigenBio

2025 BioPacific Conference
Program Book Committee

Sihong Zhou, President-Elect, CABS; Senior Scientist, Sutro Biopharma

Kay Tong, MA, President, CABS; Chief Executive Officer, N2N GXPS4U

Liang He, PhD, Scientist, Frontage

Ya'nan Wang, PhD, Senior Scientist, QLSF Biotherapeutics

Shicheng Guo, PhD, Senior Director, Arrowhead Pharmaceuticals

Vivian Liu, PhD, Lab Director, Novogene America

Xiaojun Li, Senior Graphic Designer, ca.gov

CABS 2025
Service Awards

CABS
CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY
北美华人生物医药协会

Five-Year Extraordinary Leadership

Recognizing EC members for more than 5 years of service at CABS committees

Kay Tong

Guanghui Han

Three-Year Extraordinary Leadership

Recognizing EC members for more than 3 years of service at CABS committees

Jack Zhu

Ya'nan Wang

Alex Yang

Shicheng Guo

Liang He

Wenjia Gu

Denna Kwang

Zhiqing Wang

Xinxin Li

Vivian Liu

Katherine Guan

Yuki Yang

Yang Ma

CABS 2025
Service
Awards

Outstanding Co-Chair Award

Contributions in the 2024-2025 term of CABS executive council as a co-chair

Shicheng Guo
O2

Vivian Liu
O2

Liang He
PRC

Zhiqing Wang
PRC

Lu Lu
BCD-Eclub

Qing Zhang
BCD-Eclub

Ya'nan Wang
AMC

Denna Kwang
AMC

Li Wang
SLC

Katherine Guan
SLC

Wenjia Gu
MEM

Yuki Yang
MEM

Jonathan Wong
BCD-CAN

Ava Song
BCD-CAN

Liping Meng
STC

Yan Wang
STC

Lin Wang
BCD

Guanghui Han
BCD

Yu Yang
ICC

Hesong Sun
ICC

Outstanding EC Award

Contributions in the 2024-2025 term of CABS executive council as a member

Le Cai
O2

Kaiqing Zhang
PRC

Feng Pan
BCD-Eclub

Steven Zhao
AMC

Peng'an Liu
AMC

Yujiao Zhang
AMC

Mingdian Tan
SLC

Xinxin Li
SLC

Sihong Zhou
MEM

Alex Yang
STC

Crystal Tan
AMC

The President's Volunteer Service Award

Contributions in the 2024-2025 term of CABS executive council as a volunteer

Sihong Zhou
Lifetime Achievement Award

Liping Meng
Gold Award

Liang He
Gold Award

Shicheng Guo
Gold Award

Vivian Liu
Gold Award

Denna Kwang
Gold Award

Peng'an Liu
Bronze Award

Feng Pan
Bronze Award

Outstanding Volunteer Award

Contributions in the 2024 CABS BioPacific Conference as a volunteer

Fiona Yu **Le Cai** **Guanghui Han** **Yue Wang** **Shiping Wang**
Dong Su **Amy Yang** **Yan Zhang** **Xiang Xu** **Kan Zhou**

SOUTH SAN FRANCISCO
CONFERENCE CENTER

2025 BioPacific Conference

Floor Plan

South San Francisco Conference Center

255 S Airport Blvd, South San Francisco, CA 94080



AGENDA 2025 CABS BIOPACIFIC CONFERENCE

Frontiers in Healthcare: Forging Global Impact Through Science, Innovation, & Partnership

8:00 AM – 8:45 AM	**Vendor Setup and Attendee Registration**
8:40 AM – 8:45 AM	**Welcome Remarks** ***Sihong Zhou,*** *President-elect of CABS and Organizing Committee Chair of 2025*
8:40 AM – 8:45 AM	**State of the Society** ***Kay Tong,*** *President of CABS*
9:00 AM – 10:50 AM	**Morning Session 1 -** ***Session Chair: Ya'nan Wang, PhD, AMC Co-Chair***
9:00 AM – 9:35 AM	**Keynote Speech** ***RNA Origin of Sex Biased Immunity*** ***Howard Y. Chang, PhD****, CSO and Senior VP for Global Research at Amgen*
9:35 AM – 10:05 AM	**Featured Speech:** ***Enhancing ADCs Both, Within and Outside the Tumor With Sutro's Platform Technologies Leads to a Higher Therapeutic Index*** ***Hans-Peter Gerber, PhD****, CSO of Sutro BioPharma*
10:05 AM – 10:50 AM	**Coffee Break, Network & Exhibition**
10:50 AM – 12:15 PM	**Morning Session 2 -** ***Session Chair: Shicheng Guo, PhD, PRC Co-Chair***
10:50 AM – 11:20 AM	**Featured Speech** ***Biomedicine in the Age of AI and Foundation Models*** ***Lei Xing, PhD,*** *Professor of Department of Radiation Oncology / EE/ ICME / MIPS at Stanford*
11:20 AM – 11:55 AM	**Panel Discussion** ***AI in Drug Discovery: Reality, Hype and Promise?*** ***Moderator:*** ***Zhonghua Pei, PhD****, Senior VP of Drug Discovery, Lyterian Therapeutics* ***Panelists:*** ***Lei Xing, PhD****, Professor, Stanford* ***Weian Zhao, PhD****, CEO, Aurekabio* ***Alex Taylor, PhD****, VP, Inductive Bio* ***Ci Chu, PhD****, VP, Early Discovery of Xaira Therapeutics*
11:55 AM – 12:05 PM	**Diamond Sponsor Presentation** ***Novel Proprietary LNPs and GalNac-conjugates for Delivery of Therapeutic Payloads*** ***Presenter:*** ***Claudia Qiao Lin, PhD,*** *CSO, Cosychem Technology*
12:05 PM – 12:15 PM	**Diamond Sponsor Presentation** ***Discovering Novel CRBN Molecular Glue Degraders through Integrated Generative AI and Lab Chemistry Capabilities*** ***Presenter:*** ***Hongbo Zhang, PhD****, Vice President and Head of Drug Discovery, HitChem*
12:15 PM – 1:40 PM	**Lunch Break** **Noon Session -** ***Platinum and Gold Sponsor Lunch and Learn*** ***Session Chair: Vivian Liu, PhD, MEM Co-Chair***

12:30 PM – 12:45 PM **Platinum Sponsor Presentation**
Green Lab - Sustainability in Low-Temperature Storage
Presenter: ***Gongshun Wang,*** *North America Manager, Haier Biomedical*

12:45 PM – 12:55 PM **Gold Sponsor Presentation**
Advancing Discovery-Stage Research with Next-Generation BLI: High-Performance Kinetics Without Compromise
Presenter: ***Sriram Kumaraswamy,*** *Vice President, Product Management and Marketing, Gator Bio*

12:55 PM – 1:05 PM **Gold Sponsor Presentation**
Pharmaron Corporate Capabilities Updates
Presenter: ***Lorraine Lu,*** *Senior Director of Business Development, Pharmaron*

1:45 PM – 4:20 PM **Afternoon Session 1 -** *Session Chair:* ***Lu Lu, MS, E-Club Co-Chair***

1:45 PM – 2:20 PM **Keynote Speech**
High impact pharmacology at Genentech
Margaret Porter Scott, PhD*, VP of Biochemical and Cellular Pharmacology, Genentech*

2:20 PM – 2:30 PM **2025 K. Fong Award in Life Sciences**
Moderator: ***Wentao Zhang, PhD,*** *Co-CEO, Frontage*
Presenter: ***Kenneth Fong, PhD****, Chairman, Kenson Ventures*

2:30 PM – 3:10 PM **2025 K.Fong Award Acceptance Speech**
Neurobiology of Drives and Their Competition
Presenter: ***Liqun Luo, PhD,*** *Professor of Biology, Stanford*

3:10 PM – 3:45 PM **Panel Discussion**
US-Asia Cross-Border Healthcare Investment and Entrepreneurship
Moderator: ***Cheni Kwok, PhD, CLP****, Managing Partner and Founder, Linear Dreams*
Panelists: ***Alexis Ji, PhD, MBA,*** *Founder and Managing Partner, Primer Ventures*
Ji Li, PhD*, Head of Corporate Development, Propeller Bio*
Scott Liu, PhD, *Chairman and CEO, HanchorBio*
Jenny Hsiung, MBA, *Director of Business Development & Acquisitions, AbbVie*

3:45 PM – 4:20 PM **Coffee Break, Network & Exhibition**

4:20 PM – 5:30 PM **Afternoon Session 2 -** *Session Chair:* ***Liang He, PhD, O2 Chair***

4:20 PM –4:50 PM **Featured Speech**
Targeting GPCR signaling for disease-modifying therapies to treat Parkinson's disease
Su Guo, PhD*, Professor, UCSF*

4:50 PM –5:25 PM **Panel Discussion**
From Newco to Unicorn: Building and Financing the Next Generation of Biotech Startups
Moderator: ***Janet Xiao, PhD,*** *Partner, Morrison Foerster*
Panelists: ***Carlos E. Solorzano, PhD****, Biotech investor, Ally Bridge Group*
Shalabh Gupta, MD*, Founder and CEO, Unicycive*
Chuan Sun, PhD, JD*, Partner, Morrison Foerster's Shanghai office & Hong Kong office*

5:25 PM –5:30 PM **Closing Remarks**
Kay Tong, *CABS President*
Sihong Zhou, *President- Elect*

5:30 PM – 7:45 PM **Evening Reception -** *Session Chair:* ***Wenjia Gu, PhD, BCD Co-chair; Guanghui Han, PhD, ICC Co-chair***
Highlight CABS's Charitable Mission with Focusing on Giving Back to the Community and Calling for Future Support of CABS

About Kenneth Fong

Dr. Kenneth Fong

has spent the last 41 years in the biotech industry after completing his academic pursuit in biomedical research

Dr. Kenneth Fong is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was acquired by Becton Dickinson in 1999, and Ken has continued his career as a venture capitalist with Kenson Ventures that he founded. He has since cultivated 12 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 15 companies that are worth more than $7 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Ken has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2003, he was involved with establishing the Fong Optometry and Medical Library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

About CABS **K. Fong Award in Life Sciences**

The CABS K. Fong Award in Life Sciences is an esteemed annual recognition presented to individuals who have made exceptional contributions to the fields of life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates eligible for this award must be nominated by an active member of CABS. Selection criteria are based on candidate's accomplishments in life sciences and contribution to the life science community, including one or more of the following:

- Proven achievements in therapeutic breakthroughs (including discovery, process, or clinical development), diagnostics or research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the CABS community and promotion of international collaborations in life sciences.

Past Recipients of CABS K. Fong Awards

*2024 - **Zach Sweeney, PhD,** Venture Partner at Versant Ventures, CEO and co-founder of Interline Therapeutics, CSO at Denali Therapeutics for his exceptional contributions and transformative impact on the pharmaceutical and biotechnology fields.*

*2023 - **Corey Goodman, PhD,** Managing Partner, venBio, Adjunct Prof., UC Berkeley. for outstanding contributions to science, education, entrepreneurship, and venture capital.*

*2022 - **Scott Liu, PhD,** Founder and CEO, HanchorBio, for his outstanding and pioneering contribution to the development of multiple biologic products from research to launch.*

*2021 - **John O. Link, PhD,** Vice President of Gilead Sciences and **Xian-Ping Lu,** PhD, Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD, for their extraordinary achievements in research, entrepreneurship, and innovation.*

*2019 - **John V. Oyler, PhD,** Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.*

*2018 - **Yuling Luo, PhD**. Founder, CEO and Chairman of Alamar Biosciences, and **Guoliang Yu, PhD,** Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.*

*2017 - **Yinxiang Wang, PhD,** Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule on cology drug specifically targeting cancer cells that was completely developed in China; and **Edgar Engleman, PhD,** for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.*

*2016 - **Gerald Chan, PhD,** co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.*

*2015 - **Irving Weissman, PhD,** Stanford University, for his pioneering work in stem cell research.*

*2014 - **Ge Li, PhD,** Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China; and **Hing L. Sham, PhD,** formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and Iopinavir.*

*2013 - **Peter Hirth, PhD,** Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market, and **Jean Cui, PhD,** formerly of Pfizer as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.*

Chinese American Bio/Pharmaceutical Society (CABS) Honors
Dr. Liqun Luo with the 2025 K. Fong Award in Life Sciences

South San Francisco, CA – The **Chinese American Bio/Pharmaceutical Society (CABS)** is delighted to announce **Dr. Liqun Luo,** Ann and Bill Swindells Professor of Biology at Stanford University, and Howard Hughes Medical Institute Investigator, as the recipient of the 2025 CABS K. Fong Award in Life Sciences. Marking the 12th anniversary of this esteemed accolade, the award honors Dr. Luo for his exceptional contributions to neuroscience research, education, and translational innovation. The award will be presented at the 2025 BioPacific Conference on September 13, 2025, at the South San Francisco Conference Center.

A native of Shanghai, **Dr. Luo** received his PhD from Brandeis University and completed his postdoctoral training at UCSF, following undergraduate studies at the University of Science and Technology of China. Since launching his lab at Stanford in 1996, he has become one of the foremost leaders in modern neurobiology.

Dr. Luo has pioneered the development of powerful genetic tools for neural circuit mapping, including transsynaptic tracing and intersectional genetic strategies, and has made major discoveries in how olfactory and cortical circuits are organized. His research has revealed how neurons choose their synaptic partners and how these connections affect brain function and behavior. His work has had far-reaching impact, providing critical insights into autism spectrum disorders, neurodegenerative diseases (such as Alzheimer's and Parkinson's), and psychiatric conditions. Discoveries from his lab have helped identify novel drug targets and diagnostic biomarkers, and his technologies have been licensed to industry to support gene and cell therapy research.

Dr. Luo's influence also extends to scientific education and mentorship. He is the sole author of the widely adopted textbook Principles of Neurobiology, now in its second edition. He has mentored a generation of scientists, biotech company founders and CEOs. Many of his trainees have gone on to lead companies and innovation in the biopharmaceutical industry.

Dr. Luo is a member of the U.S. National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and a recipient of the 2025 NAS Award in Neurosciences, among numerous other accolades. His service to the field includes editorial roles for top journals such as Neuron and Cell, and advisory positions with major scientific foundations.

CABS is honored to recognize Dr. Liqun Luo's outstanding achievements, which have advanced the frontiers of brain science and contributed to improved human health. His commitment to rigorous research, education, and innovation exemplifies the values of the K. Fong Award in Life Sciences.

For media inquiries and press registration for the award ceremony, please contact: *info@cabsweb.org*

Conference Speakers

2025 BioPacific Conference **Keynote Speakers**

Keynote Speaker
Howard Y. Chang, PhD, MD
CSO & SVP
Amgen

RNA origin of sex biased immunity

Dr. Howard Y. Chang is Chief Scientific Officer and Senior Vice President for Global Research. He is responsible for leading all aspects of discovery research at Amgen. Prior to joining Amgen, Dr. Chang led a research laboratory at Stanford University focused on deciphering regulatory information in the human genome for disease diagnosis and therapy. A physician-scientist and board-certified dermatologist, he served as Professor of Dermatology, Genetics, and Pathology at Stanford and Investigator of the Howard Hughes Medical Institute.

Dr. Chang is the winner of the Albany Prize, Lurie Prize in Biomedical Sciences, and NAS Award in Molecular Biology for discoveries of regulatory RNAs. He is an elected member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He is a serial entrepreneur having founded five biotech companies.

Dr. Chang holds a M.D. from Harvard Medical School, a Ph.D. in Biology from MIT, and an A.B. in Biochemical Sciences from Harvard University.

Abstract: Four out of five patients with autoimmune diseases are women, but women fare better than men for some infectious diseases and cancer immunotherapy. A female specific RNA is surprisingly the main drivers of female biased immunity. The journey to this discovery propelled new technologies, diagnostic tools, and therapeutic strategies.

Keynote Speaker
Margret Porter Scott, PhD
VP
Genentech

High Impact Pharmacology

Dr. Margaret Porter Scott is Vice President of Biochemical and Cellular Pharmacology, proudly celebrating 11 years at Genentech in 2025. Margaret and her team bring expertise in quantitative in vitro assays and the mechanistic study of molecules to Genentech's research programs across all therapeutic areas and modalities. Before joining Genentech, Margaret was the first employee of Epizyme rising to Senior Director, and was instrumental in delivering several first-in-human inhibitors including the approved drug Tazemetostat for treating epithelioid sarcoma. Before Epizyme, Margaret had over a decade of training in drug discovery through her scientific positions at Millennium, Neogenesis, Vertex, and Pfizer. Margaret received her BA from Oberlin College and her PhD from SUNY Stony Brook. Margaret has received honors including the 2014 Massachusetts Woman to Watch award and the 2023 Professional Development Award from the Genentech Women Professionals organization.

Abstract: Pharmacology is a crucial discipline for translating scientific discoveries into effective medicines. This talk will illustrate a deep understanding of the connection between structure and function through several career examples. These examples will span from early learnings in the 1990s on the intramolecular regulation of kinases to exploiting the unique function of oncogenic mutations to selectively block cancer pathways across target classes.

At Genentech, high-impact pharmacology is characterized by its ability to provide predictive insights, optimize drug candidates, and address critical questions that accelerate the path to patients. A prime example is the development of Inavolisib, a PI3K alpha inhibitor for breast cancer. Informed by lessons from prior PI3K inhibitors, Inavolisib highlights how a rigorous understanding of mechanism can be critical in optimizing best-in-class medicines. Clinical data suggests that Inavolisib, particularly with combination therapies, may offer a new standard of care.

2025 BioPacific Conference K. Fong Award Speakers

Moderator
K. Fong Award in Life Science
Wentao Zhang, PhD
Previous CABS President
Co-CEO
Frontage Laboratories, Inc.

Moderator - CABS K. Fong Award in Life Science

Dr. Wentao Zhang is the Executive Vice President of Frontage Global Drug Discovery Services. He joined Frontage in 2021 through the acquisition of Quintara Discovery, a drug discovery service company he founded in the San Francisco Bay Area in 2012. Before founding Quintara, Dr. Zhang was Senior Director of New Lead Discovery at Exelixis in South San Francisco, where he managed key drug discovery platforms and functions, including compound repository, assay development and high-throughput screening, lead optimization, DMPK operations, and safety pharmacology.

Dr. Zhang has made significant contributions to the discovery and clinical development of over twenty compounds, including two FDA-approved small molecule oncology drugs. He has served as an ad hoc member of the NIH study section on assay development & HTS. Dr. Zhang has authored and co-authored discovery data packages (biology) and preclinical DMPK study reports for IND and NDA filings, as well as over thirty scientific publications. He received his PhD in biophysical chemistry from the University of Wisconsin-Madison and his BS in Chemistry from Peking University. Additionally, he conducted research in DNA replication as a postdoctoral fellow at the University of California, Berkeley.

K. Fong Awardee
Liqun Luo, PhD
Professor
Stanford University

Presenter - Neurobiology of Drives and Their Competition

Dr. Liqun Luo was born in 1966, Dr. Luo grew up in Shanghai, China, and earned his bachelor's degree from the University of Science and Technology of China. After obtaining PhD at Brandeis University, and postdoctoral training at UCSF, Dr. Luo started his own lab at Stanford University in 1996. Together with his postdoctoral fellows and graduate students, Dr. Luo studies how neural circuits are assembled during development and how their architectures enable them to perform specific functions in adults. Dr. Luo is currently the Ann and Bill Swindells Professor of Biology at Stanford University and a Howard Hughes Medical Institute Investigator. He teaches neurobiology to Stanford undergraduate and graduate students. His single-author textbook "Principles of Neurobiology" (1st edition 2015; 2nd edition 2020) is widely used for undergraduate and graduate courses across the globe.

Dr. Luo has served on the editorial boards of *Neuron, eLife, Annu Review Neurosci, Cell, and PNAS;* advisory boards including Pew Scholars Program, Damon Runyon Cancer Research Foundation, Max Planck Institute, and Allen Institute; and selection committee for Future Science Prize. He is recipient of the McKnight Technological Innovation in Neuroscience Award, the Society for Neuroscience Young Investigator Award and Education in Neuroscience Award, the Jacob Javits Award from National Institute of Neurological Disorders and Stroke, HW Mossman Award from American Association of Anatomists, the Lawrence Katz Prize, and the Pradel Research Award and the National Academy of Sciences Award in the Neurosciences from the National Academy of Sciences. In 2012, Dr. Luo was selected to the National Academy of Sciences and the American Academy of Arts and Sciences. He is currently the chair the Cellular and Molecular Neuroscience Section at the National Academy of Sciences.

Abstract: Because of the utmost importance of water and food, animals exhibit strong innate behaviors to search for and consume water or food when they are thirst or hungry. These innate drives, or motives for action to maintain homeostasis, are also powerful means for acquiring learned skills and behaviors. In this talk, I will summarize our recent work linking thirst to motivated behavior and investigating neural dynamics underlying thirst motivation. I will further discuss how animals resolve competing needs, such as thirst and hunger, across time. Abnormal regulation of this process could lead to psychiatric disorders.

2025 BioPacific Conference **Featured Speakers**

Featured Speaker
Hans-Peter Gerber, PhD
CSO
Sutro Biopharma

Enhancing ADCs Both, Within and Outside the Tumor With Sutro's Platform Technologies Leads to a Higher Therapeutic Index

Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs. In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, focusing on next-generation ADCs that induce immunogenic cell death, and successfully secured seed funding in 2023. Hans-Peter also serves as Chairman of the Board at T-CURX, a startup in Wuerzburg, Germany, developing next-generation CAR-T cell therapies, and serves as a board member at Athebio in Zurich, Switzerland, which develops biotherapeutic compounds using Darpin technology. From 2018 to 2022, he was CSO and SVP at 3T Biosciences, where he expanded the research and development organization and raised over $50M in an oversubscribed Series A round as interim CEO. He also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021. Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda in 2021. He is a consultant to VC firms, evaluating therapeutic modalities including ADCs, bispecifics, and T-cell programs. Between 1995 and 2017, Hans-Peter held increasing responsibilities at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology biotherapeutic programs from discovery through IND filings. His work led to over 10 IND filings, including 7 ADCs and contributions to 3 BLAs, including Avastin and 2 ADCs (Mylotarg, Besponsa). As an internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed papers and holds over 100 patents. He received his MS in Biochemistry and PhD in Molecular Biology from the University of Zurich, Switzerland.

Abstract: Sutro's ADC platform is uniquely powered by a proprietary, cell-free extract protein expression system, enabling high-quality biotherapeutic manufacturing with key advantages over mammalian cell-based systems. In patients, only ~1% of ADCs administered bind to tumor antigens, leaving most to circulate and accumulate in healthy tissues, resulting in platform toxicities that limit clinical dosing. Sutro's platform-integrated ADC technologies have significantly mitigated these toxicities, achieving up to 50-fold higher exposure levels in preclinical safety studies compared to approved, conventional ADCs. Addressing the urgent need for more effective cancer therapies, Sutro is advancing dual-payload ADCs designed to deliver agents with distinct mechanisms of action, improving intratumoral efficacy and clinical durability. Preclinical results with dual-payload ADCs combining Topo1 and MMAE demonstrate deeper, more sustained anti-tumor responses than conventional single-payload ADCs. Overall, Sutro's platform and manufacturing innovations enhance the safety, efficacy, and therapeutic index of ADCs significantly, supporting the development of next-generation oncology treatments.

Featured Speaker
Su Guo, PhD
Professor & Director
UCSF

Targeting GPCR Signaling for Disease-Modifying Therapies to Treat Parkinson's Disease

Dr. Su Guo has a broad background in molecular biology, genetics, developmental biology, and neurobiology, and is interested in the molecular genetic mechanisms that regulate brain development and function. As a graduate student at Cornell University, she employed the invertebrate model organism C. elegans and made significant contributions to the discovery of RNA interference (RNAi) as well as the understanding of asymmetric cell divisions. After graduation, she became fascinated with how the brain works. As a research and postdoctoral fellow at Harvard Medical School and Genentech Inc., respectively, she carried out neurobiological studies of the development of brain neurotransmitter systems, using the vertebrate genetic model organism zebrafish. After establishing her independent research lab at the University of California, San Francisco, Dr. Guo studies the molecular genetics of neural development, maintenance, and has expanded her research into the understanding of behavior. With her research, Dr. Guo strives to make significant contributions to our basic understanding of the brain and the mind, as well as to help treat neurodegenerative and neuropsychiatric disorders.

Abstract: Parkinson's disease (PD), the most common movement disorder and the second most common neurodegenerative disorder, involves progressive loss of midbrain dopaminergic (mDA) neurons in the substantia nigra. No disease-modifying treatments exist; only symptomatic relief. In this talk, I will discuss an unbiased whole-organism-based phenotypic screen that discovered a GPCR signaling pathway, inhibition of which is neuroprotective of human pluripotent-stem cell-derived mDA neurons. GPCRs are the most druggable targets of the human genome. Our finding uncovers a promising candidate for developing neuroprotective therapies for treating PD and related neurodegenerative disorders.

Featured Speaker
Lei Xing, PhD
Professor & Director
Stanford University

Biomedicine in the Age of AI and Foundation Models

Dr. Lei Xing is the Jacob Haimson & Sarah S. Donaldson Professor and Director of Medical Physics Division of Radiation Oncology Department at Stanford University. He also holds affiliate faculty positions in Department of Electrical engineering, Institute for Computational and Mathematical Engineering (ICME), and Molecular Imaging Program at Stanford (MIPS). Dr. Xing obtained his PhD in Physics from the Johns Hopkins University in 1992 and received his Medical Physics training at the University of Chicago. His research has been focused on AI in medicine, data science, medical imaging, treatment planning and clinical decision-making, and image guided interventions. Dr. Xing is an author on more than 450 publications in high impact journals, an inventor/co-inventor on many issued and pending patents, and a co- investigator or principal investigator on numerous NIH, DOD, NSF, RSNA, AAPM, Komen, ACS and corporate grants. He is a fellow of AAPM, ASTRO, and AIMBE. He is the recipient of the 2023 Edith Quimby Lifetime Achievement Award of AAPM, which denotes outstanding scientific achievements in medical physics, influence on the professional development of others, and organizational leadership.

Abstract: AI, driven by deep learning, has garnered significant attention in recent years and is increasingly being adopted for various applications in medical imaging and multi-omics data analysis in biomedicine. The remarkable success of AI and deep learning can be attributed to their unique ability to extract essential features from big data and make accurate inferences. This talk aims to update the audience on the latest advancements in the field of omics data analysis, including foundation models and large language models. It will also address the pitfalls of current data-driven approaches, summarize recent developments in interpretable AI, and offer perspectives on the applications of AI in multi-omics data analysis and precision oncology.

2025 BioPacific Conference Panel Discussion 1
AI in Drug Discovery: Reality, Hype and Promise?

Moderator
Zhonghua Pei, PhD
SVP, Drug Discovery Lyterian Therapeutics

Dr. Zhonghua Pai is currently the Senior VP of Drug Discovery at Lyterian Therapeutics. He held various positions with increasing responsibilities at Abbott Laboratories, Genentech, Ideaya Biosciences and Neuron23, Inc. He has rich and extensive drug discovery experience in oncology, inflammatory diseases, metabolic disease (diabetes & obesity) and CNS diseases. He has made significant impact and contributions to the discovery of multiple drug development candidates at Abbott, Genentech and Ideaya and Neuron23, either as a team leader or as an individual contributor. Two of the compounds discovered by his teams are currently in active phase 2 clinical trials. He has authored or co-authored ~ 47 peer-reviewed papers, reviews and book chapters and ~ 55 patents. Zhonghua obtained his BS degree from University of Science and Technology in China (USTC), MS degree from Rensselaer Polytech Institute (RPI) and his PhD in chemistry from MIT.

Lei Xing, PhD
Professor & Director
Stanford University

Dr. Lei Xing is the Jacob Haimson & Sarah S. Donaldson Professor and Director of the Medical Physics Division of Radiation Oncology Department at Stanford University. He also holds affiliate faculty positions in the Department of Electrical Engineering, Institute for Computational and Mathematical Engineering (ICME), and Molecular Imaging Program at Stanford (MIPS). Dr. Xing obtained his PhD in Physics from the Johns Hopkins University in 1992 and received his Medical Physics training at the University of Chicago. His research has been focused on AI in medicine, data science, medical imaging, treatment planning and clinical decision-making, and image guided interventions. Dr. Xing is an author on more than 450 publications in high impact journals, an inventor/co-inventor on many issued and pending patents, and a co- investigator or principal investigator on numerous NIH, DOD, NSF, RSNA, AAPM, Komen, ACS and corporate grants. He is a fellow of AAPM, ASTRO, and AIMBE. He is the recipient of the 2023 Edith Quimby Lifetime Achievement Award of AAPM, which denotes outstanding scientific achievements in medical physics, influence on the professional development of others, and organizational leadership.

Wei'an Zhao, PhD
Founder & CEO of
Aureka Biotechnologies
Professor, UC Irvine

Dr. Wei'an Zhao is the founder and CEO of Aureka Biotechnologies and a tenured full professor at UC Irvine. At Aureka, Dr. Zhao is leading a group of passionate entrepreneurs and innovators who dare to transform the pharmaceutical industry by digitalizing therapeutic discovery through generative AI and high-throughput biology. Dr. Zhao is a serial entrepreneur and a leader in immunotherapeutic discovery technologies and has co-authored approx. 100 articles in respected journals, including *Science Translational Medicine, Nature Communications and PNAS.* Dr. Zhao has received numerous awards, including MIT's Technology Review TR35 Award, NIH Director's New Innovator Award, and UCI Innovator of the Year. Dr. Zhao was trained as a bioengineer and pharmaceutical scientist at Harvard Medical School, MIT, and McMaster University.

Alex Taylor, PhD
VP, Chemistry
Inductive Bio

Dr. Alex Taylor is a medicinal chemist passionate about drug discovery! Over almost two decades in the industry, he has contributed to more than a dozen development candidates, two of which have reached registration trials in the clinic. Before joining InductiveBio, Alex was VP, Head of Chemistry at Relay Therapeutics, where the team integrated traditional medchem approaches and predictive ADME and potency models into the identification of development candidates. He has worked across multiple small molecule classes and mechanisms of action, including reversible, covalent, chaperone, degrader, and macrocyclic peptides. Alex got his start in industry at Constellation Pharmaceuticals, applying fragment based drug design to the creation of selective bromodomain inhibitors, in collaboration with Genentech.

Before becoming a medicinal chemist, Alex completed his Ph.D. studies at Harvard University with Stuart Schreiber and was a postdoctoral fellow at MIT in the lab of Steve Buchwald. He did undergraduate research at Vanderbilt University with Ned Porter and was a Fulbright Scholar at the Universität Basel with Bernd Giese. Outside of work, Alex loves running along the Charles River and cheering for the Celtics with his family.

Ci Chu, PhD
VP, Early Discovery
Xaira Therapeutics

Dr. Ci Chu is the Vice President of Early Discovery at Xaira Therapeutics, where he leads the High-throughput Biology group and contributes to both biologics discovery and virtual cell initiatives. Chu brings over a decade of experience at the intersection of discovery biology and AI/ML. Before joining Xaira Therapeutics, he served as the Senior Director of Advanced Cellular Technologies at Insitro. In this role, he spearheaded high-content phenotyping and functional genomics teams, applying complex human iPSC disease models in neurological and metabolic indications. His research at Insitro integrated pooled transcriptomic and optical screening with advanced machine learning to uncover novel biological insights. Earlier in his career, Chu was the Genomics Tech Lead at Google[X]/Verily Life Sciences. There, he co-developed the Immune Profiler platform, which was subsequently deployed in a three-year, $90 million collaboration with Gilead to investigate inflammatory autoimmune diseases. He conducted a postdoctoral fellowship at the Genome Institute of Singapore on single-cell RNAseq platform technology, and earned his PhD from Stanford University under the mentorship of Dr. Howard Chang. During his doctoral studies, Chu invented ChIRP (Chromatin Isolation by RNA Purification), a pioneering RNA-interactome analysis method. His doctoral research, utilizing genomics, imaging, and proteomics techniques, elucidated critical mechanisms of long-noncoding RNA mediated gene regulation, including the crucial role of Xist RNA in X-chromosome inactivation. Chu holds five patents and has authored publications in prestigious journals such as Cell and Nature, which have been collectively cited over 4,000 times.

2025 BioPacific Conference Panel Discussion 2
US-Asia Cross-Border Healthcare Investment and Entrepreneurship

Moderator
Cheni Kwok, PhD, CLP
Managing Partner & Founder
Linear Dreams

Dr. Cheni Kwok is a senior biopharmaceutical executive with broad operational expertise who is specialized in corporate strategy, business development (such as merger, acquisition, licensing, project financing) and alliance management. She has initiated, negotiated and executed over 200 transactions, including 20 disclosed cross-border partnerships. Dr. Kwok is the Founder and Managing Partner of Linear Dreams LLC, a San Franscisco Bay Area based management consultancy for the life sciences industry. The firm was founded in 2011 and its engagements include a broad range of business and corporate development activities for over 80 clients in the United States, Europe and Asia.

Prior to founding Linear Dreams, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc, Director of Business Development at Celera Genomics Inc, Associate Director of Business Development at Exelixis Inc, and in various research management, technology assessment and alliance management roles at SmithKline Beecham plc (now GlaxoSmithKline plc). Dr. Kwok received a bachelor degree with first class honors in biotechnology from Imperial College London, UK a PhD in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving on the Board of Directors of the Chinese American Bio/Pharmaceutical Society (CABS).

Alexis Ji, PhD, MBA
Founder & Managing Partner
Primer Ventures

Dr. Alexis Ji is the founder and managing partner of Primer Ventures, a life science venture capital firm focused on investing in disruptive early-stage companies in life science tools and therapeutics. Founded in 2023 in Silicon Valley, Primer Ventures has rapidly made its mark in backing exceptional entrepreneurs and startups to transform innovative science and technologies into groundbreaking products and therapies.

Alexis brings two decades of expertise in venture capital and R&D in the biotech and genomics sectors. Before founding Primer Ventures, she spent over a decade at leading venture capital firms, including six years as a partner at Illumina Ventures, preceded by WuXi Ventures and ARCH Venture Partners. Her investment portfolio included early bets on industry disruptors such as Twist Bioscience (TWST) and Juno Therapeutics (JUNO, acquired by Celgene). Alexis began her professional journey in biotech R&D at major companies including Merck, Roche, and Life Technologies (Thermo Fisher).

Alexis was featured by CNBC in its report on "11 women health tech VC investors" in 2017 and named a Rising Star by Global Corporate Venture in 2018 and 2019. She holds a PhD in Molecular Genetics from Washington University in St. Louis and an MBA from the University of Chicago Booth School of Business.

Ji Li, PhD
Head of Corporate Development
Propeller Bio

Dr. Ji Li serves as Head of Corporate Development at Propeller Bio, responsible for financing, business development, and certain business operations functions. Previously, as Acting Chief Business Officer at Proteologix, he was instrumental in its acquisition by Johnson & Johnson for an upfront cash payment of $850 million. Dr. Li joined Proteologix from LAV, where he was an Entrepreneur-in-Residence. Before LAV, he was Vice President of Business Development, Finance & Operations at Immune-Onc Therapeutics. Prior to Immune-Onc, he was Director of Marketing Strategy & Operations at Natera, where he launched Signatera, a personalized circulating tumor DNA test for molecular residual disease (MRD) assessment and recurrence monitoring. Ji started his career at Navigant Consulting, advising biopharmaceutical companies on product & portfolio strategy, commercial planning, product launch, operational excellence, and digital health. Dr. Li holds a BS from Peking University and a PhD from Columbia University.

Scott Liu, PhD
Founder, Chairman & CEO
HanchorBio

Dr. Scott Liu is the Founder, Chairman, and CEO of HanchorBio Inc, a clinical-stage global biotechnology company advancing next-generation immunotherapies in immuno-oncology. At the core of HanchorBio's innovation is the Fc-based Design of Biologics (FBDBTM) platform—a proprietary technology that enables the development of novel biologics capable of activating both the innate and adaptive immune systems to combat a wide range of cancers. The company's lead asset, HCB101, is currently undergoing Phase 1B/2 clinical trials in gastric cancer (GC) and head and neck cancer (HNC). Additional indications—including triple-negative breast cancer (TNBC) and colorectal cancer (CRC)—are in development across the U.S., China, and Taiwan. A second program, HCB301, is in Phase 1a trials for solid tumors in both the U.S. and China.

Dr. Liu is a seasoned life sciences entrepreneur and biotech company builder. He was a global partner at Fosun International Limited and the Co-founder, President, and CEO of Shanghai Henlius Biotech Inc, a commercial-stage biopharmaceutical company listed on the Hong Kong Stock Exchange (2696.HK) with a market capitalization exceeding USD $5 billion. Under his leadership, Henlius advanced over 30 biologics—including biosimilars, novel monoclonal antibodies, and bispecific antibodies—and successfully launched five commercial mAb products in China and Europe. With over 30 years of experience in biologics development, Dr. Liu has extensive expertise in corporate strategy, portfolio management, GMP operations, and CMC regulatory affairs. Prior to founding HanchorBio and Henlius, he held senior roles including:

- Vice President of Scientific Affairs at United Biomedical Inc.
- Founding Director of Biologics QC at Bristol-Myers Squibb (USA)
- Director of Quality Analytical Laboratories at Amgen (USA)

Dr. Liu received his PhD in Biology from Purdue University and completed his postdoctoral training at Stanford University.

Jenny Hsiung
Director of Business
Development & Acquisitions
AbbVie

Jenny Hsiung is the Director of Business Development & Acquisitions at AbbVie. Her expertise includes sourcing opportunities, structuring deals to align with internal and external business needs, and negotiating term sheets and contract provisions successfully. Before her current role in Business Development, Jenny was with AbbVie's Alliance Management team, where she supported partnerships in various stages of development and commercialization. Prior to joining AbbVie, Jenny spent two years in Greater China in Corporate Development roles. She began her career as a Process Engineer at Genentech.

Jenny holds a MEng and a BS degree in Bioengineering from UCSD and a MBA degree from Harvard Business School.

2025 BioPacific Conference Panel Discussion 3

From Newco to Unicorn: Building and Financing the Next Generation of Biotech Startups

Moderator
Janet Xiao, PhD, JD
Partner, Morrison Foerster

Dr. Janet Xiao focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet's clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. She works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products.

Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients' complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, "Janet's work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge."

Dr. Xiao is the Head of firm's China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Bio/pharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term.

Chuan Sun, PhD, JD
Partner Morrison Foerster's Shanghai office & Hong Kong office

Dr. Chuan Sun is the Managing Partner of Morrison Foerster's Shanghai office and Co-Managing Partner of its Hong Kong office. He focuses his practice on life sciences and sophisticated technology, media, and telecom (TMT) transactions, complex IP/commercial matters, and cross-border M&A transactions across Greater China.

Dr. Sun has significant experience in strategic corporate-commercial, life sciences and technology transactions, including pharma collaboration and licensing, pharmacovigilance, clinical trial, clinical supply, manufacturing, distribution, supply and franchising arrangements, and IP licensing arrangements across multiple industries. His life sciences, TMT, and IP regulatory experience includes human genetic resources, telecommunications, e-commerce, internet, cyber security, data privacy, and cloud computing, as well as telematics.

Dr. Sun regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.

He has more than 20 years of experience in both Asia and the United States. Prior to joining Morrison Foerster, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.

Dr. Sun has been named as Dealmaker of Asia 2024 by Asian Legal Business. He recently advised Ensem Therapeutics, Inc., a biotechnology company focusing on high-value and difficult-to-drug oncology targets, on its partnership with BeiGene, Ltd., a global biotechnology company. This deal has won China Business Law Journal's Deals of the Year Award 2024.

Shalabh Gupta, MD
Founder Unicycive

Dr. Shalabh Gupta is the founder of Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategy role at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS Investment Bank; and as an equity researcher covering biotechnology companies at Rodman & Renshaw (currently HC Wainwright). Dr. Gupta previously served as a medical advisor to Synageva BioPharma Corporation and as an advisor to New York University (NYU) Langone Medical Center's Office of Technology Transfer. Dr. Gupta is also the founder and Chief Executive Officer of Globavir, which had licensed diagnostic technology from Stanford university, which was then partnered with global commercial diagnostic companies. Dr. Gupta is an advisor to the UCSF Innovation Center, a role he has held since 2020. Since 2012, and has also been an advisor to SPARK, Stanford University School of Medicine. Dr. Gupta previously served on the board of directors for the Beall Center for Innovation and Entrepreneurship at the University of California Irvine, Paul Merage School of Business.

Before his roles in business and finance, Dr. Gupta was an attending physician at NYU Medical Center and a clinical faculty member at the NYU School of Medicine. Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. Dr. Gupta completed his internship in Internal Medicine, medical residency in Physical Medicine and Rehabilitation, and research fellowship in Cardiopulmonary Rehabilitation at NYU School of Medicine. Dr. Gupta received his MPA in Health Care Finance and Management from NYU's Robert F. Wagner Graduate School of Public Service and his MD from Jawaharlal Institute of Postgraduate Medical Education & Research, India.

Dr. Gupta has been in several leadership roles throughout his academic and professional career. He was elected president of the Resident Physicians Council during his residency training, representing approximately 1,500 resident physicians in physical medicine and rehabilitation across the US. He also served on the Board of Directors at the Wagner Alumni Association, and was elected to the Board of Directors of the UC Irvine Beall Center for Innovation and Entrepreneurship in 2018.

Carlos E. Solorzano, PhD
Biotech investor
Ally Bridge Group

Dr. Carlos E. Solorzano is a Principal for the private equity strategy at Ally Bridge Group focused on investments in biotech. Before joining Ally Bridge, he was in the investment teams at Section 32 and Pivotal bioVenture Partners focused on private biotech companies. Before his career in private equity, Dr. Solorzano was in the BD and Corporate Strategy team at Ultragenyx and was a Senior Associate in the equity research teams at Deutsche Bank and Oppenheimer & Co. Dr. Solorzano has a BS in Chemical Engineering from Cal Poly Pomona, earned a PhD in Pharmacology from UC Irvine, and was an NIH postdoctoral scholar at UC San Francisco.

2025 BioPacific Conference **Sponsor Speakers**

Diamond Sponsor
Claudia Qiao Lin, PhD
Chief Strategic Officer

Novel Proprietary LNPs and GalNac-conjugates for Delivery of Therapeutic Payloads

Dr. Claudia Lin started her career in R&D, and pre-clinical drug development, after receiving her Ph.D in cell and molecular biology from UC Berkeley. She expanded her expertise to translational research of novel biologics and various areas of drug development. Over the past 25 years, she became an industry leading expert in biologics product development holding several high impact roles, including CMC and quality leadership positions for Genentech, ROCHE, and Head of Quality for Bayer in the US. A decade ago, Claudia took her Western biopharma expertise to China, where she played a critical role in the development of China's biotech industry, especially in product development, GMP manufacturing, quality and regulatory compliance. After working for a leading China biopharma as their Quality Head, she founded her own CMC consulting company which played instrumental roles in supporting many of the "China-first for global" product launches for novel biologics and cell and gene therapy products. Her leadership in bridging China and the West biotech won a strategic alliance for her company with a leading global CDMO for biologics QC testing service platform, further solidifying her influence for the Chinese biotech industry. Since returning to the US in 2024, Claudia is serving the global biologics community as a seasoned business development and technical advisor helping innovative drug developers around the world advance their product development through strategic and technical consulting.

Abstract: Recent Cosychem has developed a proprietary library of ionizable lipids encompassing over 10,000 unique structures. We have successfully discovered over 10 LNPs that efficientlytarget delivery of payloads to organs including liver, lungs, spleen, muscle and blood-brain barrier. Cosychem's LNP platforms empower targeted delivery solutions for advanced therapies such as siRNA/mRNA/nucleic acid drugs, CRISPR gene editing, and CAR-T cell therapies.

Cosychem also delivers a portfolio of established GalNAcdelivery molecules (including compounds such as L96, THA C6, NAG37, NAG15, NAG25), high-purity key intermediates, molecular building blocks, and customized GalNAc synthesis services.

Diamond Sponsor
Hongbo Zhang, PhD
VP of Drug Discovery Service
Hong Kong office
HitChem

Discovering Novel CRBN Molecular Glue Degraders through Integrated Generative AI and Lab Chemistry Capabilities

Dr. Hongbo Zhang is the Vice President of Drug Discovery Service at HitChem, where he leads early-stage small-molecule discovery platforms. His work encompasses the design of compound libraries, delivery of integrated chemistry services, and 2D molecular generation. Since joining HitChem in 2019, he has directed multiple early discovery programs and successfully advanced several small-molecule candidates into clinical development.

With over 11 years of experience in innovative small-molecule drug R&D and project management, Dr. Zhang has led the discovery and preclinical development of four small-molecule drug candidates that have received clinical trial approval.

Dr. Zhang earned his Ph.D. in Organic Chemistry from Nankai University. He has served as a medicinal chemistry lead and project manager in both CROs and leading biotech companies, with a strong track record of translating scientific innovation into clinical assets. His expertise spans medicinal chemistry, preclinical development, and cross-functional project leadership.

Abstract: Developing effective CRBN-based molecular glue (MG) degraders remains a significant challenge due to their shallow binding pockets and the need for selective, patentable scaffolds. At HitChem, we leverage generative AI and Stucture based rational design to develop focused CRBN MG libraries tailored for high-throughput screening and early-stage discovery. Our platform combines AI-driven molecular generation with expert medicinal chemistry, enabling the creation of over 18,000 diverse and synthesizable MG compounds featuring validated CRBN warheads. These libraries enhance hit rates, reduce screening costs, and facilitate the discovery of selective degraders. In this presentation, we will showcase our rational design, library structures, and in-house chemistry capabilities in accelerating hit identification and lead optimization.

Platinum Sponsor
Gongshun Wang
USA Sales Manager
Haier Biomedical

Green Lab - Sustainability in Low-temperature Storage

Gongshun Wang, North America Manager at Haier Biomedical, will present "Green Lab – Sustainability in Low-Temperature Storage" at the 2025 CABS BioPacific Conference. The presentation will highlight Haier Biomedical's pioneering role in sustainable and intelligent low-temperature storage, featuring industry-leading technologies and solutions that are shaping the future of green laboratories in the life sciences sector.

Gold Sponsor
Sriram Kumaraswamy
VP of Product Management & Marketing
Gator Bio

Advancing Discovery-Stage Research with Next-Generation BLI: High-Performance Kinetics Without Compromise

Sriram Kumaraswamy is Vice President of Product Management and Marketing at Gator Bio, where he leads global strategy for advancing next-generation label-free analysis platforms. With over 25 years of experience in the life sciences tools industry, Sriram has played a key role in commercializing innovative biosensing technologies, including bio-layer interferometry (BLI), across applications in drug discovery, bioprocessing, and analytical development.

Prior to joining Gator Bio, Sriram held senior leadership roles at Danaher, Sartorius, Nicoya Lifesciences, and ForteBio, where he helped drive market adoption of label-free platforms through customer-centric product development and strategic marketing.

Sriram holds a background in chemistry and brings a deep understanding of both scientific workflows and the evolving needs of biopharma researchers. He is passionate about making advanced analytical technologies more accessible, scalable, and impactful across the drug development pipeline.

Abstract: Label-free technologies play a critical role in the characterization of biomolecular interactions during early-stage drug discovery. Yet many platforms present trade-offs between throughput, data quality, and cost of ownership. Gator Bio's next-generation bio-layer interferometry (BLI) systems offer a new balance delivering high-resolution kinetics, robust quantitation from crude samples, and true walk-away automation, all with significantly reduced consumable and operational costs.

This talk will highlight how discovery teams can achieve faster screening, more reproducible data, and broader application flexibility without the compromises of legacy systems. Case examples will illustrate how Gator Bio supports real-world workflows in antibody screening, affinity ranking, and process development, empowering teams to move from hit to lead with greater confidence and efficiency.

Gold Sponsor
Lorraine Lu
Senior Director of Business Development
Pharmaron

Pharmaron Corporate Capabilities Updates

Lorraine Lu is Senior Director of Business Development at Pharmaron, where she leads strategic collaborations with San Francisco biotechnology companies to accelerate small-molecule drug discovery. With more than fifteen years of experience in the contract research organization (CRO) industry, she has built deep expertise in drug discovery services, combining a strong scientific foundation with proven business development leadership.

Since joining Pharmaron, Lorraine has partnered with more than 120 biotech companies, providing real-time support to advance their pipelines. Her efforts have contributed to significant milestones. She is widely recognized for her ability to translate complex scientific capabilities into clear value propositions, enabling biopharmaceutical partners to progress critical programs efficiently.

2025 CABS BioPacific Conference Session Chairs Team

Chair
Morning Session 1
Ya'nan Wang, PhD
Sr. Scientist
QLSF Biotherapeutics

Chair
Morning Session 2
Shicheng Guo, PhD
Sr. Director
Arrowhead Pharmaceuticals

Chair
Noon Session
Vivian Liu, PhD
Director
Novogene

Chair
Afternoon Session 1
Lu Lu, MS
MicuRx Pharmaceuticals

Chair
Afternoon Session 2
Liang He, PhD
Frontage Laboratories

Chair
Evening Reception Session
Wenjia Gu, PhD
Sutro Biopharma

Chair
Evening Reception Session
Guanghui Han, PhD
PTM BIO LLC

Chinese American Bio/Pharmaceutical Society (CABS)

Recognized as a PVSA Certifying Organization

Dr. Liang He, *Chair of the Office Operation Committee, Advisor of the Public Relationship & Communication Committee, is leading the CABS PVSA program to build a vibrant community of engaged volunteers and advance the mission of CABS.*

We are thrilled to announce that, under the leadership of **Dr. Liang He,** Chair of the Office Operation, Advisor of Public Relationship Committee, the Chinese American Bio/Pharmaceutical Society (CABS) has been recognized as an official certifying organization for the President's Volunteer Service Award (PVSA) since March 2025. This prestigious recognition allows CABS to honor the outstanding contributions of our members and volunteers who dedicate their time and skills to serve our communities.

We look forward to celebrating the achievements of our volunteers and encouraging more members to engage in meaningful service. Together, we continue to make a difference in the biopharmaceutical field and beyond.

2024-2025 Selected CABS Activities

The 2024 BioPacific Conference

The 2024 BioPacific Conference, alternatively recognized as the 25th Annual Conference of the Chinese American Bio/Pharmaceutical Society (CABS), took place on September 7th, 2024, at the South San Francisco Conference Center in California.

This exceptional gathering featured a notable lineup of speakers, panelists, and moderators, enjoyed generous support from 48 sponsors, and drew the participation of over 500 attendees. The remarkable success of this event owes its existence to the invaluable contributions and active engagement of our esteemed speakers, sponsors, attendees, members of the organizing committee, and dedicated volunteers.

The theme of the conference was "Global Biopharma Innovations in the Age of AI & Big Data". The conference comprised 3 keynote speakers, a speech for the K. Fong Award, 4 scientific presentations, 3 dynamic panel discussions, and an interactive breakout workshop session, all led by prominent figures from both the industry and academia.

Opening Session: Biopharma Innovations in a Global Change of AI and Big Data

The first presentation was delivered by Dr. Sabine Kapasi. Dr. Sabine Kapasi highlighted the transformative role of AI and big data in biopharma, from drug discovery to personalized medicine. She emphasized the need for global collaboration, data quality, and inclusion of the Global South to drive equitable digital health innovation.

Dr. Stacey Ma's keynote highlighted Gilead's rapid growth and the transformative role of AI in biopharma. She emphasized data, computing power, and models as AI pillars, showcased innovations like Bayesian optimization and self-driving labs, and stressed the need for responsible AI use and organizational readiness for digital transformation.

Dr. Kenneth Fong presented the 2024 CABS K. Fong Award to Dr. Zachary Sweeney, Operating Partner at Versant Ventures and Professor at UCSF Quantitative Biosciences Institute.

The presentation emphasized leveraging human genetic, proteomic, and metabolomic data to uncover disease mechanisms and accelerate drug discovery. It highlighted advances in functional genomics, protein signaling, and machine learning to develop targeted therapies for complex diseases like inflammation, neurodegeneration, and neuropsychiatric disorders through a data-driven, precision approach.

Session 1: Data Driving Discovery to Drug, A Journey from Bench to Bedside

Dr. Sonja Schrepfer and Sana Biotechnology's hypoimmune (HIP) technology uses gene editing to evade immune rejection, enabling off-the-shelf cell therapies without immunosuppression. Launching four clinical programs in 2024, this approach targets cancers and autoimmune diseases, offering scalable, accessible treatments and potentially revolutionizing global cell-based therapy.

Han Lim of DeepCure showcased AI-driven small molecule drug discovery using robotic synthesis at the 2024 BioPacific Conference. Targeting inflammatory diseases, DeepCure's custom compound libraries and automated synthesis platform accelerate discovery beyond traditional methods, enabling rapid, cost-effective development of novel therapies through iterative AI-guided design, synthesis, and testing cycles.

Dr. Khaled Sarsour highlighted Johnson & Johnson's use of synthetic data and AI to enhance clinical development. Emphasizing high-quality real-world data, he discussed integrating causal inference with machine learning to create unbiased predictive models, envisioning hybrid trials using real and synthetic data to accelerate and improve drug development.

Session 2: Accelerating Drug Development with Impactful Data

Dr. Hong Wang's keynote highlighted novel predictive and translational safety approaches, including lab-in-loop, computational models, and in vitro

NAMs, to accelerate drug development. A case study on predicting drug-induced liver injury using AI and multiple parameters showcased reduced costs, improved safety, and animal testing reduction through industry collaboration.

Dr. Wei Dong led a panel with industry experts discussing critical data in drug safety, innovative data collection, and AI applications in drug development. Panelists shared successful technology use cases and emphasized effective frameworks for responsibly leveraging AI to advance safer, more efficient drug development processes.

Session 3: Biopharma Discovery and Application with AI/ML and Big Data

Section III discusses Biopharma Discovery and Application with AI/ML and Big Data. This section included the talk from Dr. Don Kirkpatrick and the panel discussion which was led by Mark Wesson.

Dr. Don Kirkpatrick highlighted mass spectrometry proteomics' transformative role in drug discovery, enabling precise, large-scale protein measurement and analysis of disease-relevant responses. Advances in speed and sensitivity allow detailed mechanistic studies, complementing genomics, and advancing understanding of cellular responses to drug treatments and perturbations.

The second panel, moderated by Mark Wesson, featured experts from law, pharma, and AI discussing entrepreneurial strategies in AI and Big Data. They covered patent challenges, exit strategies, and partnering with major pharma, offering key insights for entrepreneurs navigating innovation, IP, and market opportunities in the evolving biotech landscape.

Session 4: Data for Investment: Global Perspectives for Strategic Investment and Financial Sustainability

The panel highlighted early pharma partnerships, timely fundraising, and non-dilutional funding as vital for biotech startups. Emphasizing adaptive financing aligned with growth, experts stressed strategic investor selection, balancing grants with venture capital, and learning from diverse industries to ensure financial sustainability and long-term success in a challenging funding landscape.

The conference concluded with a closing address by CABS President Dr. Jessica Sun and CABS President-Elect Kay Tong. In their closing remarks, they introduced the history of CABS, tracing its evolution from its inception to its current state and elucidating the mission that continues to drive CABS forward. They highlighted the pivotal role of collective dedication, expertise, and unwavering passion, emphasizing their instrumental role in advancing the biopharmaceutical industry.

In closing, we wish to extend our heartfelt gratitude once more to all the distinguished speakers, enthusiastic sponsors and attendees, the hardworking organizing committee, and the dedicated volunteers who contributed to the resounding success of this conference. It was your unwavering commitment and boundless passion for CABS and the broader biopharmaceutical community that truly propelled this event to greatness. We are deeply appreciative of your collective efforts and look forward to the prospect of reconnecting with you in future events.

CABS Workshop – Journey from Discovery to IND to Early Development

On November 9, 2024, CABS hosted a well-attended workshop at Hanhai Biolabs in Burlingame, CA, drawing around 100 participants. Centered on the theme "Journey from Discovery to IND to Early Development," the event featured five expert speakers who shared key insights into the drug development process.

Dr. Zhonghua Pei (Neuron23) opened with strategies for lead optimization and challenges in achieving potency and selectivity. Dr. Yang Tian (AusperBio) traced the evolution of high-throughput screening (HTS), highlighting the integration of AI and data quality. Dr. Shichang Miao (PBSS) discussed balancing pharmacokinetics and pharmacodynamics, emphasizing flexibility beyond standard rules. Dr. Xiaoting Wang (Amgen) explored nonclinical safety assessments, with a focus on predictive tools and target liability. Dr. Ron Najafi (Emery Pharma) addressed nitrosamine impurities and the importance of contamination risk assessments.

Covering oncology, inflammation, and immunotoxicology, the workshop combined technical depth with practical case studies. Attendees engaged actively during Q&A sessions and gained valuable networking opportunities.

CABS extends sincere thanks to the speakers, sponsors, attendees, and volunteers for making the event a success—highlighting the power of collaboration in accelerating drug discovery and development.

2025 CABS Lunar New Year Gala

On January 20th, over 200 guests gathered at the Fair Oaks Community Center in Redwood City, CA, for the 2025 CABS Lunar New Year Gala, celebrating the Year of the Snake. Hosted by the Social Life Committee of the Chinese American Biopharmaceutical Society (CABS), the event featured 15 vibrant performances including folk dance, martial arts, singing, and instrumental music. Attendees enjoyed traditional Spring Festival activities such as calligraphy and riddle guessing, along with delicious Chinese cuisine.

Raffle prizes and sponsor giveaways added excitement, while guests connected with sponsors and explored Chinese culture in a festive setting. We thank our volunteers, performers, and sponsors—GenY Financial Advisors, Golden Bank, Golden Gate Scientific, and Kyinno Biotechnology—for making this event a success.

CABS Launches 2025 with Investor Forum and Roadshow in San Francisco

On January 15, the Chinese American Biopharmaceutical Society (CABS) kicked off 2025 with its Investor Forum at Morrison & Foerster's San Francisco office during JP Morgan Week. Hosted by CABS President Kay Tong, the event highlighted 2024 accomplishments and ongoing mentorship and career development efforts.

Brigid Bondoc of Morrison & Foerster discussed the life sciences policy outlook under a potential new administration, raising concerns over regulatory changes and agency staffing. Two expert panels explored industry trends, including adapting to high interest rates, Chinese partnerships, IPO outlooks, and the importance of strategic planning amid global uncertainties.

Following the forum, CABS resumed its post-pandemic Roadshow, featuring ten innovative companies. Highlights included Kortuc's cancer radiotherapy enhancer, Synlico's AI gene analysis platform, Karnelian X's neoantigen-specific T cells, and MicuRx's antibiotic for pulmonary disease. Other presenters showcased advancements in RNA delivery, oxygen therapeutics, T cell engagers, and digital health.

The Roadshow drew strong interest from investors and attendees, underscoring CABS's role in fostering innovation, collaboration, and investment in the biopharmaceutical space. Special thanks to long-time partner Morrison & Foerster for co-hosting this impactful event.

The CABS 2025 Data Science Summer Intern Program

The CABS 2025 Data Science Summer Intern Program is the flagship training initiative of the Chinese American Biopharmaceutical Society (CABS), offering a 12-week, hands-on experience at the intersection of AI, data science, and drug development.

This year, 12 exceptional students were selected from top universities including Stanford, UC Berkeley, Cornell, Harvard, MIT, Johns Hopkins, and the University of Pennsylvania. Chosen through a highly competitive process, they bring strong backgrounds in bioinformatics, computational biology, and biomedical data science.

Interns work on impactful, real-world projects such as AI-powered target discovery, omics integration, RWE analysis, and LLM-driven literature mining. Each project is mentored by industry leaders from top biopharma companies, ensuring scientific rigor and career-relevant experience.

Founded and led by Dr. Shicheng Guo, Senior Director of Translational Genetics and Data Science at Arrowhead Pharmaceuticals, the program is designed to bridge academic talent with real-world industry challenges while fostering innovation and professional growth.

Beyond technical training, the program offers weekly seminars, tool workshops (R, Python, ChatGPT API), and cross-functional collaboration. It culminates in a public symposium where interns present their findings to a panel of experts.

The CABS Summer Intern Program is more than an internship—it's a launchpad for emerging leaders in life sciences, offering world-class mentorship, a strong professional network, and real industry impact.

CABS 2025 Summer Internship Project:
Efficacy Lens AI Agent

The Efficacy Lens AI Agent leverages Google's Gemini API to revolutionize how clinical trial literature is reviewed and compared. Designed to automatically extract, organize, and analyze key results from pharmaceutical publications, the tool generates clear, actionable comparison tables within five minutes—dramatically reducing the time and effort required for comprehensive review. By processing data from multiple trials, the AI agent enhances comparative analysis, surfaces subtle efficacy differences, and helps researchers make evidence-based decisions faster. Its automation minimizes the risk of human oversight and standardizes how clinical outcomes are evaluated across studies. This not only accelerates the research workflow but also improves the clarity and consistency of the results presented to decision-makers. The Efficacy Lens AI Agent addresses a major bottleneck in drug development: the labor-intensive and error-prone process of manually reviewing and comparing trial data. Under the mentorship of Dr. Ying Yang, summer intern Baixue (Doris) Zhang successfully transformed the concept into a practical solution with significant potential for adoption in clinical and regulatory settings. The project exemplifies how cutting-edge AI can complement human expertise, delivering rapid, reliable, and reproducible insights that improve the quality and speed of biomedical research.

CABS 2025 Summer Internship Project:
Target Finder AI Agent



The Simple AI Target Finder Agent is an innovative bioinformatics tool designed to rapidly identify and prioritize therapeutic targets for specific diseases. Developed using OpenAI's ChatGPT-4o on Google Colab, the agent integrates multiple high-value biomedical databases, including GWAS Catalog, Open Targets, GTEx, BioGRID, PubMed, DrugBank, and ChEMBL. By translating disease names into standardized database terms and automating the analysis process, the agent produces a ranked target report in minutes, replacing a manual process that could take weeks. The pipeline applies systematic scoring and ranking algorithms based on genetic evidence, gene expression patterns, protein interactions, and druggability profiles. This approach ensures robust prioritization while minimizing human bias. The project showcases how AI-driven automation can drastically accelerate early-stage drug discovery by synthesizing diverse datasets into actionable insights. The tool also highlights reproducibility and scalability, enabling rapid iteration across multiple diseases. Guided by Dr. Zhuoqing Fang from Stanford University, intern Jun Xiao demonstrated exceptional skill in merging computational and biomedical knowledge. The project's success illustrates the transformative potential of AI in translational research, where fast, accurate, and transparent target discovery is critical for advancing therapeutic innovation.

CABS Clinical Development Workshop

On April 26, 2025, the CABS Science and Technology Committee (STC) hosted a highly successful Clinical Development Workshop in Burlingame, CA, drawing over 80 attendees from the biotech and pharmaceutical sectors. This dynamic half-day event featured expert speakers from Genentech and ChemoCentryx/Amgen, offering in-depth insights into clinical trial design, statistical strategies, pharmacology, and protocol development.

Dr. Shichang Miao opened with an overview of clinical development stages, sharing lessons from his 16-year journey developing Tavneos. Dr. Sara Glickstein Bar-Zeev (Genentech) followed with insights on Clinical Development Plans (CDPs) and study design, emphasizing strategic planning, protocol quality, and the growing role of AI. Dr. Chen Chen (Genentech) presented on statistical foundations, highlighting randomization, endpoint selection, and sample size calculation. Dr. Miao returned to discuss clinical pharmacology studies, offering practical examples and regulatory insights.

In the final session, Dr. Glickstein detailed key protocol components, stressing clarity and regulatory compliance. The event concluded with a lively panel discussion moderated by Dr. Alex Yang, covering adaptive trials, global regulations, and the FDA's evolving guidance.

The workshop ended with a networking lunch, energized by new ideas and connections. With glowing feedback, the 2025 CABS Clinical Development Workshop proved both educational and inspiring.

The Morrison Foerster (MoFo) Series Event

IP Essentials and Investor Perspectives in Life Sciences

On May 14th, Morrison Foerster (MoFo) and CABS successfully launched the first session of the MoFo Series—IP Essentials and Investor Perspectives in Life Sciences—at MoFo's Palo Alto office.

Dr. Janet Xiao opened the event, followed by Dr. Lisa Silverman, who provided an overview of intellectual property (IP) types, patentability criteria, the patent lifecycle, and strategies for leveraging provisional filings and regulatory exclusivity. She also addressed IP considerations in AI, covering patents, copyrights, trade secrets, and inventorship.

Dr. Xiao continued with a deep dive into IP due diligence, ownership, and freedom to operate (FTO), using hypothetical scenarios and case studies. She emphasized the importance of early FTO assessment and strategic patent portfolio management, especially for biotech startups.

After a networking break, CABS President Kay Tong introduced the organization, followed by a panel discussion moderated by Yuying (Kate) You, featuring five industry experts. The panel shared insights on launching biotech and AI ventures, highlighting the value of strong IP, experienced teams, and market alignment. They recommended a hybrid IP strategy and proactive planning to reduce risks.

The event concluded with an engaging Q&A and networking session, leaving attendees with actionable strategies for IP-driven success in life sciences.

Formation, Fundraising, and Licensing in Life Sciences

The MoFo Series event "Formation, Fundraising, and Licensing in Life Sciences" provided key legal and strategic guidance for biotech startups. Jim Ryan and Katie from MoFo's Venture Capital Group outlined the importance of forming a Delaware corporation, maintaining clean records, and managing equity grants and 83(b) elections. Common pitfalls included unclear IP ownership, poor trade secret protection, and employment missteps. Fundraising strategies such as SAFEs, convertible notes, and equity rounds were discussed, with emphasis on legal compliance and investor alignment.

In "The Success Story of Proteologix," founder David Shen shared how a focus on bispecific antibodies for autoimmune diseases—and avoiding crowded fields—helped the company raise $155M and achieve a successful exit to Johnson & Johnson. He stressed strategic focus, quality data, team alignment, and long-term vision over hype.

The panel discussion featured David Shen, Jim Ryan, Stephanie Sharron, and Josh Xiao, who provided insights on early incorporation, IP protection, and managing dual roles. Cross-border challenges, especially with Chinese partners, were addressed with advice on legal safeguards and cultural awareness. Panelists emphasized building differentiated products, disciplined fundraising, and avoiding risky contract terms. The session concluded with an interactive Q&A and valuable networking.

Career Development Workshop

"Unlocking Opportunities: Make the Job Market Work for You"

On June 21st, CABS hosted a successful Career Development Workshop at Hanhai Silicon Valley Center, Burlingame, for biotech professionals. Dr. Yan Wang opened the event, followed by introductions from Yu Yang and CABS president-elect Sihong Zhou.

Toby Freedman discussed diverse biotech career paths and practical job search strategies, emphasizing aligning skills with goals and leveraging networking. Rachel Kindt highlighted the importance of leadership skills, effective communication, and personal branding for long-term success. Kelly Law shared interview tips and guided participants through practical exercises to build confidence. Jonathan Wong explained the biotech recruiting process, urging patience amid lengthy hiring timelines.

A lively panel addressed LinkedIn profile tips, job application strategies, and career transitions, noting industry preferences against frequent job hopping and advising clarity on role expectations. Attendees learned to creatively showcase skills when moving from academia or adjacent fields.

The event concluded with a Q&A, lunch, and networking. CABS thanked Intellipro Group for sponsoring and hopes the workshop empowered professionals to unlock new career opportunities in biotech and pharma.

CABS Online Worshop

Cross-Border Biotech/Pharma Transaction Case Studies

On July 11, 2025, CABS hosted a successful webinar, "Cross-Border Biotech/Pharma Transaction Case Studies," attracting over 300 participants from the U.S. and China. Moderated by Guanghui Han and opened by CABS President Kay Tong, the event highlighted U.S.-China collaboration and upcoming BioPacific Conference plans.

Dr. Cheni Kwok discussed cross-border deal structures, emphasizing alignment of seller and buyer goals, and shared case studies on licensing and partnerships. She highlighted challenges like partner selection and clear communication.

Dr. Janet Xiao focused on legal aspects, particularly intellectual property (IP) due diligence. She detailed key issues including patent protection, freedom to operate, export controls, and data privacy. Dr. Xiao stressed early IP analysis and robust patent strategies to ensure market exclusivity.

The Q&A session featured discussions on market dynamics, patent strategies, and the importance of early IP diligence. Participants engaged actively, reflecting strong interest in navigating international biotech deals.

This webinar provided valuable insights into deal structures, partnership strategies, and IP challenges, reinforcing CABS's role as a bridge between U.S. and Chinese biotech communities. Building on this momentum, CABS looks forward to advancing cross-border collaboration through the upcoming BioPacific Conference and future programs.

Hiking by SLC

Spring in the Bay Area is both poetic and picturesque, with natural beauty that requires no enhancement. In March, the Chinese American Biomedical Society (CABS) Social Life Committee organized two well curated hiking events, offering participants an opportunity to appreciate the region's scenic landscapes while fostering camaraderie and deeper social connections.

The Purisima Creek Trail in Half Moon Bay is located within the publicly accessible Purisima Creek Redwoods Open Space Preserve. The area features a diverse network of trails, ranging from tranquil, moisture rich forest paths to elevated routes offering panoramic views of the surrounding valley. The experience was both rejuvenating and visually stunning.

The second hike explored Sunol Peak, a lesser-known but equally captivating destination in the East Bay. This location features three strenuous trails and one of moderate difficulty, spanning 4 to 8 miles in distance and reaching elevations above 2,000 feet posing a meaningful challenge to both physical endurance and mental resilience.

CABS members demonstrated exceptional vitality and determination, successfully navigating each trail. These events not only promoted physical well-being but also created lasting memories, reinforcing a sense of community through shared experiences in nature's embrace.

Dragon Boat Race by SLC

On June 7, 2025, the CABS team proudly participated in the Bay Area Dragon Boat Novice Race, a prominent annual event organized by Bay Area Dragon to promote community engagement and team building. Set against the picturesque backdrop of Foster City, the event featured cultural festivities, food trucks, live music, and a welcoming atmosphere for families and pets alike. The CABS team demonstrated exceptional teamwork, resilience, and camaraderie throughout three competitive rounds, earning well-deserved recognition and applause. Sincere appreciation is extended to all team members for their dedication and to the volunteers whose efforts contributed to the success of this meaningful event.

CAN Kick-off Event

On April 19, 2025, CABS successfully launched its CAN (Career Advisory Network) Program with a well-attended kick-off event. The program, which drew an impressive 29 mentors and 47 mentees, is designed to foster a supportive community and provide invaluable guidance to emerging leaders in the life sciences.

The evening began with the program's co-chairs introducing the mission of CAN: to empower the next generation of biopharmaceutical professionals through a six-month framework of one-on-one mentoring and group networking. This was followed by a series of insightful presentations from selected mentors and mentees.

After the formal presentations, attendees moved into an active networking session. Participants seized the opportunity to connect in a vibrant atmosphere, discussing shared interests and career aspirations. The event showcased the collaborative spirit of the CABS community and successfully set a positive tone for the months of mentoring ahead.

全和诚
COSYCHEM

Cosychem is a biotechnology company (Tianjin, China), dedicated to empowers nucleic acid drug developers with cutting-edge LNP technology and nucleic acid drug raw materials—from early discovery to pre-IND and clinical phases—offering both non-GMP and GMP-compatible solutions.

Our Core technology is a Proprietary Lipid Nanoparticle (LNP) delivery Platform

- Built on a novel cationic lipid library with independent intellectual property
- Over 10,000 lipid molecules, with 5,000 new structures added yearly
- Over 10,000 in vitro and 1,000 in vivo screens
- Superior liver targeting vs SM-102, tunable for liver, lung, spleen, tumor, heart and brain.
- Support mRNA, siRNA, DNA, CRISPR-based payloads
- 12 Innovation IPs

High Encapsulation **Low Toxicity** **GMP Scalability** **Strong Stability**

Cosychem' service

Nucleic Acid Drug raw materials: Phosphoramides, GalNAc, LNP raw materials, NTPs, Custom synthesis

Nucleic Acid Drug Delivery System: Integration, Co-development, and Licensing support

Why COSYCHEM?

Our mission is to empower Clients with

Innovation **Flexibility**

Efficiency **Partnership**

www.cosychem.com

全和诚 COSYCHEM | NUCLEIC ACID DRUG DELIVERY SYSTEMS

1 Proprietary Lipid Nanoparticle (LNP) Platform Introduction

Engineered for precision, Designed for performance.

Cosychem' s proprietary LNP platform delivers next-generation nucleic acid therapeutics with unmatched targeting flexibility and proven performance.

- **Built on a novel cationic lipid library**: with independent IP
- **10,000+ lipid molecular structures**: with 5,000+ added yearly
- **Extensive screening data**: >10,000 in vitro & 1,000 in vivo studies
- **Tunable Organ-specific delivery**: liver, lung, spleen, muscle, tumor, heart and brain, Superior liver targeting vs SM-102
- **Versatile payload compatibility**: support mRNA, siRNA, DNA, CRISPR-based payloads
- **12 innovation-driven patents**: supporting a robust IP foundation



Key Features & Advantages

√ High encapsulation √ Low toxicity √ Strong stability √ GMP Scalability √ Organ–precise targeting

Liver–targeting	Lung–targeting	Spleen–targeting	Muscle–targeting



HitChem

HitChem integrates advanced cheminformatics and cutting-edge language models to accelerate early-stage small molecule drug discovery. Our proprietary platform combines AI-driven molecule design with ultra-high-throughput screening to speed up hit identification and lead generation.

Our Products

HitChem offers a diverse range of compound libraries for high-throughput screening, available in either powder or solution form, with solutions conveniently pre-plated onto 384-well plates. Each library is carefully curated, and compounds are randomly quality-controlled by experienced chemists to ensure reliability and enhance rational drug design. This meticulous selection process supports more efficient hit identification and optimization—ultimately delivering a higher hit rate for your discovery campaigns.



Our HTS Library

53,000+	14,000+	49,000+	9,000+	1,000+
Diversity	CNS	Molecular Glue	Covalent	Cyclic Peptide

www.hit-chem.com

marketing@hit-chem.com

https://www.linkedin.com/company/hitchem/

LinkedIn Website

HitChem

Our Services

HitChem provides fully integrated services for the early-stage discovery of small molecules, supporting projects from hit identification to lead optimization. Our service platform features a **2D Molecular Generation Model (2DMG)** that rapidly explores chemical space from a given fragment or scaffold, generating diverse, drug-like structures for hit optimization or novel scaffold discovery.

Complementing this, our **integrative chemistry services** deliver end-to-end support, including High-Throughput Virtual Screening (HTVS), Structure–Activity Relationship (SAR) analysis, Computer-Aided Drug Design (CADD), and hit similarity searching—ensuring a streamlined workflow that accelerates discovery and maximizes project success.

Hit Finding
- Structure Based Virtual Screening
- Ligand Based Virtual Screening
- Library Screening

Hit To Lead
- Similarity Search
- Scaffold Hopping
- Hit Follow-Up Design

Lead Optimization
- Rational Design
- 2D Molecule Generation

Chemisty Service
- Medicinal Chemistry
- Synthetic Chemistry
- Analytical Chemistry
- High Throughput Chemistry

Our Accomplishments

14	6	2	2
Hit	Lead	PCC	Clinical

1,000+	10,000+	1,000+	10%
FEP	MD	HTVS	Hit rate

Our Virtual Libraries

10 billion+	100 million+	10 million+	1 million+
Diversity	Molecule Glue	Cyclic Peptides	Covalent

www.hit-chem.com

marketing@hit-chem.com

https://www.linkedin.com/company/hitchem/

LinkedIn

Website


MORRISON
FOERSTER
We are proud to support the
CABS 2025
BioPacific Conference
MOFO
LIFE SCIENCES + HEALTHCARE
© 2025 The Morrison & Foerster Foundation

Haier Biomedical

Intelligent Protection of Life Science

Introduction

Haier Group, founded in 1984, is a leading global provider of better life and digital transformation solutions.In 2024, Haier Group achieved a global revenue of USD 55.9 billion, with a total profit of USD 4.2 billion, Haier Group has a global workforce of 120,000 employees.

Haier Biomedical was established in 2005 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019 (stock code: 688139). The Company aims to create the best user experience for a wide range of user groups such as hospitals, biotechnology enterprises, universities & colleges, scientific research institutions, centres for disease control and prevention, plasma stations, and primary public health authorities. The Company mainly engages in two major business fields: life sciences and medical innovation.

Comprehensive Smart Product Solutions

Biobank Solution

ULT freezers, automated biobank systems, liquid nitrogen storage, sample preprocessing, and consumables + sample management platforms

Smart Laboratory Solution

Incubators, centrifuges, and biosafety cabinets + smart lab control systems

Smart Pharmacy Solution

Solar-powered vaccine solutions and smart vaccine + digital public health platforms

Blood Bank Solution

Intelligent blood solutions and blood technology + plasma-blood integration networks

Public Health Solution

Medicine storage boxes and smart medical + pharmaceutical management platforms

Analytical Solution

Analysis Instruments

Clients

Life Sciences
Pharmaceutical companies, universities, and research institutions

Healthcare & Public Health
Hospitals, disease control and prevention centers, blood banks, and primary healthcare facilities

150+	700+	40+
Countries and regions	Distributors	International organizations

Global Presence

abbvie

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives. Our commitment is measured by the impact we make – to patients, to our communities, and to the world. Our approximately 50,000 employees strive to make a remarkable impact that lasts, driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity. Today our products help more than 60 million people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow.

Learn More Link: https://www.abbvie.com/

Resource Links:

- Learn About Partnering with AbbVie:
  https://www.abbvie.com/science/partner-with-us/partnering-days.html
- AbbVie Ventures: Investing in Transformational Scientific Opportunities:
  https://www.abbvie.com/science/partner-with-us/abbvie-ventures.html
- Our Pipeline:
  https://www.abbvie.com/science/pipeline.html
- AI & Data Convergence:
  https://www.abbvie.com/science/areas-of-innovation/ai-and-data-convergence.html
- Get to Know AbbVie Bay Area:
  https://www.abbvie.com/join-us/bay-area-opportunities.html




Thank You!

CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY
北美华人生物医药协会

CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY (CABS)

Website: *www.cabsweb.org*

General information: *Info@CABSweb.org*

Membership: *Membership@CABSweb.org*

Fundraising: *Fundraising@CABSweb.org*

Mailing Address: 268 Bush Street, #1888, San Francisco, CA 94104, USA

CABSweb.org

CABS Member Registration

CABS Linkedin

CABS Newsletter